NeuroSense Therapeutics (NASDAQ:NRSN) Trading Down 4.2% – What’s Next?

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) fell 4.2% on Friday . The company traded as low as $0.4201 and last traded at $0.4204. 95,020 shares changed hands during trading, a decline of 77% from the average session volume of 411,943 shares. The stock had previously closed at $0.4389.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded NeuroSense Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

NeuroSense Therapeutics Trading Down 4.2%

The stock has a market capitalization of $15.88 million, a price-to-earnings ratio of -0.78 and a beta of 1.62. The firm’s fifty day moving average price is $0.58 and its 200 day moving average price is $0.73.

Insider Buying and Selling

In other news, CFO Or Eisenberg purchased 250,000 shares of the stock in a transaction dated Tuesday, June 16th. The stock was acquired at an average cost of $0.80 per share, for a total transaction of $200,000.00. Following the completion of the transaction, the chief financial officer directly owned 1,504,050 shares in the company, valued at approximately $1,203,240. This represents a 19.94% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Alon Ben-Noon purchased 250,000 shares of the stock in a transaction dated Tuesday, June 16th. The shares were purchased at an average price of $0.80 per share, with a total value of $200,000.00. Following the completion of the transaction, the chief executive officer owned 4,534,233 shares of the company’s stock, valued at approximately $3,627,386.40. This trade represents a 5.84% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 27.40% of the stock is owned by insiders.

Institutional Investors Weigh In On NeuroSense Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. Two Sigma Investments LP acquired a new position in NeuroSense Therapeutics during the 3rd quarter worth about $26,000. Jane Street Group LLC purchased a new position in NeuroSense Therapeutics during the 2nd quarter valued at about $54,000. Yorkville Advisors Global LP acquired a new position in NeuroSense Therapeutics in the 2nd quarter valued at about $56,160. Finally, Squarepoint Ops LLC grew its position in NeuroSense Therapeutics by 91.0% in the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after acquiring an additional 45,450 shares in the last quarter. Hedge funds and other institutional investors own 1.04% of the company’s stock.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.